May 16, 2022 — A new report by a team of cardiologists from the Heart & Vascular Hospital, Hackensack Meridian Hackensack University Medical Center that compares the hemodynamics of cardiac shock in patients wi

May 16, 2022 — The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature 12 studies as Late-Breaking Clinical Science and Featured Clinical Research. An annual meeting covering cutting-edge research and techniques for structural heart interventions, TVT will take place June 8-10, 2022, at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois.

May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) market, achieving around $958 million in sales by 2025, according to GlobalData, a leading data and analytics company.

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced successful completion of patient enrollment in the company’s AcQForce Flutter Investigational Device Exemption (IDE) clinical trial which enrolled 110 patients at 21 sites globally.

May 13, 2022 — Vascular diseases are public enemy number one: the leading killers worldwide, accounting for nearly a third of all human deaths on the planet.

May 12, 2022 — Abbott announced a new partnership with Women as One to launch a new program designed to train more female and underrepresented physicians to pursue clinical trial research and help recruit clinical trial participants from historically underrepresented groups.

The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032, expanding at a CAGR of 6.2% over the 2022-2032 time frame.

The global cardiogenic shock market was valued at US$ 3.29 Bn in 2021, and is expected to reach US$ 6.32 Bn by 2032, expanding at a CAGR of 6.2% over the 2022-2032 time frame.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now